Geisinger Medical Laboratories Test Catalog
FECAL LACTOFERRIN, EIA |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB2267 Geisinger Epic ID: 45112 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Fresh stool | |
Preferred collection container: |
||
Specimen required: |
1-2 ml fresh liquid, semisolid, or formed stool in a sterile cup with no preservatives | |
Special notes: |
Fecal samples from breast-fed infants should not be used with this assay. This test may not be appropriate for immunocompromised patients. See Microbiology Collection Appendix . | |
SPECIMEN PROCESSING |
||
Transport temperature: |
Transport specimens to laboratory at 2-8ºC (2-25ºC is also acceptable). | |
Specimen stability: |
2-25ºC up to one week. | |
Rejection criteria: |
Specimens collected in Protofix CLR, ETM, Formalin, PVA, or SAF. Improperly labelled or collected specimens. Insufficient volume. | |
TEST DETAILS |
||
Interpretation guide: |
Negative, no lactoferrin detected. | |
Critical values/courtesy alerts: |
Positve, lactoferrin detected. | |
Additional information: |
The Leuko EZ Vue test detects elevated levels of lactoferrin released from fecal leukocytes as a marker of intestinal inflammation. This test may not be appropiate in an immunocompromised patient | |
CPT code(s): |
83630 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Fecal leukoferrin EIA | |
Methodology: |
Alere Leuko EZ Vue |
|
Synonyms: |
WBC, Fecal WBC, Fecal leukocytes, White Blood Cells, Stool lactoferrin, fecal lactoferrin FLEIA
|
|
Clinical significance: |
A positive test result indicates an increased level of fecal lactoferrin and warrants additional testing. Inflammation diarrheas are caused by pathogens such as Shigella, Salmonella, Camplyobacter jejunii, and Clostridium difficile. In inflammatory diarrheas fecal leukocytes are found in feces in large numbers. This test may not be appropiate for immunocompromised patients. | |
Doctoral Director(s:) |
Donna Wolk PhD, D(ABMM), Raquel Martinez, PhD, D(ABMM) | |
Review Date: | 12/31/2022 |